Stocks
Avanos Medical Financial Statements (AVNS) |
||||||||||
| Avanos Medicalsmart-lab.ru | % | 2023Q3 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 01.11.2023 | 21.02.2024 | 02.05.2024 | 31.07.2024 | 30.10.2024 | 30.10.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 171.3 | 173.3 | 166.1 | 171.7 | 170.4 | 681.5 | |||
| Operating Income, bln rub | 1.20 | 22.2 | 7.40 | 16.1 | 12.0 | 57.7 | ||||
| EBITDA, bln rub | ? | 13.1 | 30.3 | 18.9 | 23.0 | 24.4 | 96.6 | |||
| Net profit, bln rub | ? | -3.70 | 10.5 | -0.900 | 1.80 | 4.30 | 15.7 | |||
| OCF, bln rub | ? | 29.1 | 12.7 | -8.00 | 27.8 | 23.0 | 55.5 | |||
| CAPEX, bln rub | ? | 3.90 | 5.90 | 4.10 | 5.90 | 3.00 | 18.9 | |||
| FCF, bln rub | ? | 25.2 | 6.80 | -12.1 | 21.9 | 20.0 | 36.6 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 94.3 | 75.2 | 87.4 | 79.5 | 80.9 | 323.0 | ||||
| Cost of production, bln rub | 75.8 | 75.9 | 71.3 | 76.1 | 77.5 | 300.8 | ||||
| R&D, bln rub | 6.10 | 6.80 | 7.00 | 6.30 | 7.20 | 27.3 | ||||
| Interest expenses, bln rub | 4.70 | 3.30 | 3.10 | 3.10 | 3.20 | 12.7 | ||||
| Assets, bln rub | 1 725 | 1 692 | 1 661 | 1 658 | 1 656 | 1 656 | ||||
| Net Assets, bln rub | ? | 1 222 | 1 236 | 1 228 | 1 222 | 1 230 | 1 230 | |||
| Debt, bln rub | 306.7 | 209.1 | 214.7 | 218.3 | 202.2 | 202.2 | ||||
| Cash, bln rub | 107.1 | 87.7 | 75.8 | 92.2 | 89.0 | 89.0 | ||||
| Net debt, bln rub | 199.6 | 121.4 | 138.9 | 126.1 | 113.2 | 113.2 | ||||
| Ordinary share price, rub | 20.2 | 22.4 | 19.9 | 19.9 | 24.0 | 21.5 | ||||
| Number of ordinary shares, mln | 46.8 | 46.2 | 46.2 | 45.9 | 46.0 | 46.0 | ||||
| Market cap, bln rub | 946 | 1 036 | 920 | 914 | 1 105 | 991 | ||||
| EV, bln rub | ? | 1 146 | 1 158 | 1 059 | 1 040 | 1 219 | 1 104 | |||
| Book value, bln rub | 188 | 201 | 200 | 201 | 215 | 215 | ||||
| EPS, rub | ? | -0.08 | 0.23 | -0.02 | 0.04 | 0.09 | 0.34 | |||
| FCF/share, rub | 0.54 | 0.15 | -0.26 | 0.48 | 0.43 | 0.80 | ||||
| BV/share, rub | 4.03 | 4.34 | 4.33 | 4.39 | 4.66 | 4.66 | ||||
| EBITDA margin, % | ? | 7.65% | 17.5% | 11.4% | 13.4% | 14.3% | 14.2% | |||
| Net margin, % | ? | -2.16% | 6.06% | -0.54% | 1.05% | 2.52% | 2.30% | |||
| FCF yield, % | ? | 3.87% | 1.41% | 1.45% | 4.57% | 3.31% | 3.69% | |||
| ROE, % | ? | -4.53% | -5.00% | -5.07% | 0.63% | 1.28% | 1.28% | |||
| ROA, % | ? | -3.21% | -3.65% | -3.74% | 0.46% | 0.95% | 0.95% | |||
| P/E | ? | -17.1 | -16.8 | -14.8 | 118.7 | 70.4 | 63.1 | |||
| P/FCF | 25.9 | 71.0 | 69.2 | 21.9 | 30.2 | 27.1 | ||||
| P/S | ? | 1.26 | 1.47 | 1.35 | 1.34 | 1.62 | 1.45 | |||
| P/BV | ? | 5.02 | 5.16 | 4.59 | 4.54 | 5.15 | 4.62 | |||
| EV/EBITDA | ? | 14.6 | 16.9 | 14.7 | 12.2 | 12.6 | 11.4 | |||
| Debt/EBITDA | 2.54 | 1.77 | 1.92 | 1.48 | 1.17 | 1.17 | ||||
| R&D/CAPEX, % | 156.4% | 115.3% | 170.7% | 106.8% | 240.0% | 144.4% | ||||
| CAPEX/Revenue, % | 2.28% | 3.40% | 2.47% | 3.44% | 1.76% | 2.77% | ||||
| Avanos Medical shareholders | ||||||||||
